Internal tandem duplication (ITD) of the fms-like tyrosine kinase 3 (FLT3) gene is a gain-of-function mutation common in acute myeloid leukaemia (AML). It is associated with inferior prognosis and response to chemotherapy. Single base mutations at the FLT3 tyrosine kinase domain (TKD) also leads to a gain of function, although its prognostic significance is less well defined because of its rarity. The clinical benefits of FLT3 inhibition are generally limited to AML with FLT3-ITD. However, responses are transient and leukaemia progression invariably occurs. There is compelling evidence that leukaemia clones carrying both ITD and TKD mutations appear when resistance to FLT3 inhibitors occurs. Interestingly, the emergence of double ITD and TKD mutants can be recapitulated in vitro when FLT3-ITD þ leukaemia cell lines are treated with mutagens and FLT3 inhibitors. Furthermore, murine xenotransplantation models also suggest that, in some cases, the FTL3-ITD and TKD double mutants actually exist in minute amounts before treatment with FLT3 inhibitors, expand under the selection pressure of FLT3 inhibition and become the predominant resistant clone(s) during the drug-refractory phase. On the basis of this model of clonal evolution, a multipronged strategy using more potent FLT3 inhibitors, and a combinatorial approach targeting both FLT3-dependent and FLT3-independent pathways, will be needed to improve outcome.
INTRODUCTION
Acute myeloid leukaemia (AML) is a group of heterogeneous diseases sharing in common an abnormal increase in myeloblasts in the circulation and bone marrow. Intensive chemotherapy and allogeneic haematopoietic stem cell (HSC) transplantation are the principal treatment modalities. However, these approaches have reached an impasse, with a cure rate of only 30-40%. 1 Internal tandem duplication (ITD) of the fms-like tyrosine kinase 3 (FLT3) gene is a gain-of-function mutation, and represents one of the most common genetic alterations in AML, occurring in nearly 30% of cases.
2,3 FLT3 is a class III receptor tyrosine kinase consisting of five extracellular immunoglobulin-like domains, a transmembrane domain, a juxtamembrane domain and two tyrosine kinase domains (TKD1 and TKD2). 4 It is highly expressed in haematopoietic stem and progenitor cells. 5 Upon binding to FLT3 ligand, it dimerizes and autophosphorylates, resulting in activation of tyrosine kinase activity, which in turn activates the phosphoinositide-3-kinase/AKT and RAS/mitogen-activated protein kinase pathways. 6, 7 FLT3-ITD involves an in-frame duplication of 3-400 basepairs at the juxtamembrane or TKD1 domains. It results in alteration of cellular signalling, including the constitutive activation of FLT3 independent of ligand binding; 8 activation of STAT5 (signal transducer and activator of transcription 5) via SRC kinase; 9 phosphorylation of a transcription factor FOXO3A; 10 downregulation of the equilibrative nucleoside transporter 1 for cytarabine; 11 and induction of reactive oxygen species production. 12 These molecular consequences result in damage 13 and defective repair of DNA, and increased cellular proliferation and resistance to apoptosis. [14] [15] [16] Comprehensive description of normal and aberrant FLT3 signalling has been reviewed previously.
4, [14] [15] [16] Clinically, FLT3-ITD occurs most frequently in AML with normal karyotype, trisomy 8, t(6;9) and t (15;17) , 2, 3 and is generally associated with leukocytosis on presentation. 17 Although the complete remission (CR) rate does not appear to be affected, AMLs with FLT3-ITD have higher relapse rates 18 and therefore inferior disease-free and overall survivals, 19 particularly in AML with larger ITD size, 20 higher allelic burden 21 and multiple ITDs. 22 Therefore, FLT3 inhibition has become a legitimate therapeutic option, and clinical trials of FLT3 inhibitors in AML have been ongoing for a decade. [23] [24] [25] To date, more than 20 small molecule inhibitors against FLT3 have been reported, of which eight of them have been evaluated in clinical trials. 26 Structurally, most of these inhibitors are heterocyclic compounds, inhibiting FLT3 activity by competing with ATP for binding to the ATP-binding pocket of the TKD. Functionally, they are generally multikinase inhibitors. Their clinical activities appear to be mediated by FLT3 inhibition, so that their efficacies are limited to AML carrying FLT3-ITD, and correlated with inhibition of FLT3 phosphorylation and hence its downstream signalling effectors. [27] [28] [29] [30] [31] Although inhibition of FLT3 may be achievable, clinical efficacy is less than convincing, being limited by the invariable leukaemia progression despite continuous treatment. 24 Comprehensive reviews on the mechanisms of drug resistance have been published. 24, [32] [33] [34] [35] [36] [37] [38] [39] The proposed mechanisms include persistent activation of FLT3 signalling due to overexpression of FLT3 ligand and protein, activation of antiapoptotic signals and protection of leukaemiainitiating cells (LIC) by the bone marrow niche (Table 1) . Although therapeutic strategies have been formulated on these propositions, they are based primarily on in vitro data and laboratory observations.
There is now compelling clinical evidence that the resistance to FLT3 inhibitors may arise from the emergence of FLT3-ITD þ clones carrying additional TKD mutations. A similar concept of evolution of resistant clones 40 has been generated to explain resistance to multikinase inhibitors in chronic myelogenous leukaemia (CML) 41 and solid organ malignancies. 42 This review focuses on the clinical and laboratory evidence of clonal evolution in FLT3-ITD, and proposes testable models that may lead to improved strategies to overcome drug resistance in FLT3-ITD þ AML.
FLT3-ITD: DRIVER MUTATION OR SECONDARY EVENT?
A central theme in cancer genetics is the identification of the driver mutation that leads to transformation of the cancer-initiating cell. In over 80% of FLT3-ITD þ AML, the ITD is present at diagnosis and relapse, suggesting that it may be the driver associated with initiation of the leukaemia. 43, 44 Xenotransplantation experiments have also shown that FLT3-ITD þ cells dominate the engrafting leukaemic clones, implying that FLT3-ITD occurs at the level of LIC. 45, 46 Furthermore, knock-in of FLT3-ITD in mice results in a myeloproliferative disease that transforms into full-blown AML when additional genetic alterations, such as NUP98-HoxD13, are present. 47 These data can be considered as evidence to suggest that FLT3-ITD may be a driver mutation, and that secondary mutations are required for frank leukaemogenesis. On the other hand, it has also been found that FLT3-ITD may occur only at diagnosis and not relapse, or vice versa, 44, 45 suggesting that ITD may be a secondary event developing in subclones of leukaemia cells or acquired during leukaemia progression. 48 These observations underscore the intrinsic heterogeneity of AML, and that a particular genetic alteration may have distinctive pathogenetic roles depending on where it occurs in the hierarchy of leukaemic haematopoiesis. 48 This heterogeneity may also account for the variable responses to FLT3 inhibitors observed in clinical trials. inhibitors induced a response rate ranging between 46 and 100%. In addition to disease heterogeneity, the varying responses might have been due to different definition of responses and the number of patients studied. However, the majority of responses was restricted to reduction of blast counts and haematological improvement. CR, or complete remission with incomplete haematological recovery (CRi), only occurred in 5-35% of cases. Furthermore, these remissions were not durable. Hence, it has been suggested that FLT3 inhibitors may best be used as a bridging therapy to bring patients into remission for a subsequent haematopoietic stem cell transplantation. Interestingly, FLT3 inhibitors might induce responses in leukaemias apparently without FLT3 mutations (Table 3) . However, responses were mainly reduction in blast counts, and CR/CRi has not been reported. These responses were most likely related to the multikinase activities of these drugs instead of FLT3 inhibition.
CLINICAL EFFICACY OF FLT3 INHIBITORS
To overcome the transient responses induced by FLT3 inhibitors, the addition of concomitant or sequential chemotherapy appears to be an attractive option. In one study of relapsed AML patients with FLT3 mutation (ITD, N ¼ 104; TKD, N ¼ 11) treated with chemotherapy followed by lestaurtinib, 49 a CR/CRi rate of 26% was observed, comparable with that of 21% in patients without FLT3 mutation. There was no difference in survivals. In another study of 15 cases of relapsed AML with FLT3 mutation (ITD, N ¼ 13; TKD, N ¼ 2) treated with concomitant chemotherapy and sorafenib, 55 a CR/CRi rate of 100% was found, which was significantly better than that of 66% in 36 cases without FLT3 mutation. There was, however, no apparent difference in survivals. In a more recent study in which 13 cases of newly diagnosed AML with FLT3 mutation (ITD, N ¼ 9; TKD, N ¼ 4) was treated with chemotherapy and either concomitant or sequential midostaurin, 56 the CR/CRi rate was 92%, which was higher than that of 74% in 27 cases without FLT3 mutation. Similar to previous studies, there was again no difference in survivals.
What these studies showed was that FLT3 inhibitors could safely be combined with chemotherapy, leading to comparable or better CR/CRi rates. However, the clinical problem of AML with FLT3 aberration is not a low CR rate, but increased relapses. None of the previous studies showed survival improvement, suggesting that the addition of chemotherapy failed to prevent relapses in such cases. Furthermore, owing to protocol design, the mechanistic bases of relapses following an initial response had not been investigated. Therefore, data from these studies were unhelpful in the rational design of strategies to overcome the increased relapse risks conferred by FLT3 aberrations. Prospective trial involving larger number of patients examining the effect of combined FLT3 inhibitor and chemotherapy in FLT3-mutated AML is ongoing, 56 and it remains to be seen if a beneficial effect on relapse may be demonstrated clinically.
FLT3-TKD MUTATIONS: IMPACTS ON AML
FLT3-TKD mutations occur mostly in exon 20, with substitution of aspartic acid by tyrosine at codon 835 the most common (Table 4) . FLT3-TKD mutations stabilize the activation loop of the open ATP-binding configuration, so that it is similar to ITD in leading to constitutive FLT3 activation. However, FLT3-TKD mutations occur much less frequently, and do not appear to have the same adverse prognostic implications as FLT3-ITD. When transduced into murine haematopoietic stem cells, FLT3-TKD mutations result in lymphoproliferative diseases instead of myeloid neoplasms, indicating that the signalling pathways deranged may be different from those of ITD. 9, 57 Furthermore, coexistence of FLT3-ITD and TKD mutations (referred to as the 'double mutant' hereafter) was infrequent (0.2-2%), suggesting that TKD mutations occur rarely, and that the two mutations might not necessarily have cooperative advantages in the absence of selection pressure.
LOSS OF RESPONSE TO FLT3 INHIBITORS: CLINICAL EVIDENCE OF EMERGENCE OF RESISTANT CLONES
Despite variable initial responses, AML treated with FLT3 inhibitor monotherapy almost always progresses. This observation is reminiscent of CML treated by the multikinase inhibitor imatinib, where emergence of imatinib-resistant clones may occur in up to 30% of patients. 58 Whereas in CML resistance can often be shown to be due to mutations in the ABL1 part of the BCR-ABL1 fusion gene, the genetic basis of non-responsiveness to FLT3 inhibitors is not fully understood. Leukaemic cells from a patient with FLT3-ITD treated with midostaurin showed, at relapse but not on presentation, the presence of a single amino-acid substitution N676K within the TKD, 59 which appeared to confer resistance to midostaurin in vitro. The appearance of an A848 TKD mutation was also demonstrated in a patient with chronic myelomonocytic leukaemia treated with alternating courses of sunitinib and sorafenib. 60 In a heavily pretreated cohort of 13 patients with FLT3-ITD, sorafenib monotherapy resulted in significant clearance of marrow blasts in 12 of them. 61 Comparison of FLT3 genotype before and after sorafenib treatment in six patients demonstrated, in addition to ITD, the presence of TKD D835H mutation in one and D835Y mutation in three patients at leukaemia progression. Abbreviations: AML, acute myeloid leukaemia; b.i.d., twice daily; BR, blast response; CR, complete remission; CRp, CR without platelet recovery; FLT3, fms-like tyrosine kinase 3; HI, haematological improvement; i.v., intravenous; PR, partial remission.
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These mutations were not identified by a sensitive allele-specific polymerase chain reaction before sorafenib treatment. Similarly, emergence of FLT3-ITD clone carrying the TKD D835/I836 mutation was recently reported in 14 of 58 patients with FLT3-ITD þ AML treated with FLT3 inhibitors. 62 Genetic analysis of six FLT3-ITD þ AML patients treated with sorafenib and standard chemotherapy also demonstrated TKD D651G(H), G619C, I687F and E858K mutations at relapse in three patients. 63 With AC220 monotherapy, emergence of TKD D835 and F691 mutations was demonstrated in all eight patients who subsequently progressed with continuous therapy. 64 These observations provided unequivocal clinical evidence that the loss of response to FLT3 inhibitors was associated with the emergence of TKD mutations.
RESISTANCE TO FLT3 INHIBITORS: OBSERVATION IN MURINE MODELS
In clinical studies where FLT3-TKD mutations have appeared in addition to ITD during disease progression, it has remained unclear whether the double mutants are present before or are acquired after treatment with FLT3 inhibitors. One possibility is that the double mutant clone may have been too small to be identified from the pre-treatment examples. To test this hypothesis, patients with FLT3-ITD þ AML treated with sorafenib, who responded initially but progressed with the additional appearance of ITD/TKD double mutants, were studied. Xenotransplantation of leukaemia samples obtained on presentation and apparently lacking TKD mutations in immunodeficient mice had resulted in engraftment of double ITD/TKD mutants, often overwhelming ITD þ clones. 61 This observation demonstrated that double mutant clones albeit rare were present before treatment with FLT3 inhibitor, but were selected upon monotherapy with FLT3 inhibitor, which might have accounted for the subsequent leukaemia progression.
TKD MUTATIONS RESISTANT TO FLT3 INHIBITORS: OBSERVATIONS IN THE LABORATORY
Data supporting TKD mutations as a mechanism for resistance to FLT3 inhibitors come predominantly from laboratory observations. On the basis of a cell line derived from a patient with relapsed FLT3-ITD þ AML (MOLM-13), FLT3-TKD D835Y mutation could be induced by 6-7 weeks of in vitro treatment with increasing concentrations of tandutinib. The resultant line became resistant to subsequent treatment with AC220 and sorafenib. 65 It was possible that the TKD mutation might have pre-existed in a small leukaemia subclone in MOLM-13 cell line, which was acquired during chemotherapy and selected upon tandutinib treatment. This proposition was supported by the finding that, in a mouse B-lymphoid cell line Ba/F3 transduced with FLT3-ITD, prolonged treatment with the FLT3 inhibitors midostaurin, semaxinib and sorafenib resulted in TKD mutations of significantly higher frequencies if the line had a prior exposure to the mutagen N-ethyl-N-nitrosourea (ENU), as compared with the control line. This observation implied that genotoxic chemotherapy might predispose to the development of TKD mutation when subsequent selection pressure by FLT3 inhibitors is imposed. This suggestion is supported by data from next-generation sequencing, which showed that additional gene mutations could be induced by chemotherapy during AML treatment.
Importantly, each FLT3 inhibitor induced its distinctive TKD mutant pattern, suggesting non-overlapping resistance profile to FLT3 inhibitors in this cellular model. Intriguingly, in another study in which MOLM-13 cells were treated with increasing concentrations of midostaurin or HG-7-85-01 for up to 13 weeks, no TKD mutations could be demonstrated. 37 Therefore, the occurrence of TKD mutation may depend not only on FLT3-ITD, but also on prior treatment regimens and the FLT3 inhibitors used.
THE DRUG-RESISTANT MODEL
On the basis of these observations, we propose a model that may provide a theoretical framework on which future therapeutic intervention can be rationally designed (Figure 1) . At leukaemia initiation, FLT3-ITD occurs as a driver event in some cases of AML. The resulting genomic instability leads to additional mutations at the TKD, although these are rare events. Intensive chemotherapy used for induction and consolidation induces and/or enhances the occurrence of gene mutations and provides the basis for clonal selection. At subsequent relapses and salvage treatment with FLT3 inhibitors, the FLT3-ITD þ myeloblasts either undergo apoptosis 38, 67, 68 and/or differentiation, 61,69 resulting in prompt reduction or clearance of blasts. However, the double mutant clones are mostly insensitive to the inhibitors. In particular, the FLT3-TKD mutations at the activation loop or gatekeeper residue confer allosteric hindrance to the binding of the inhibitors and stabilize the activation loop of the open ATP-binding configuration. 64, 70, 71 The TKD mutations to be selected may depend on the specific FLT3 inhibitors used and the sequence specificity of prevailing FLT3-ITD. Once expanded, the double mutant clones progress rapidly and survive on alternative signalling pathways that are either FLT3 dependent or independent, leading to clinical resistance. Studies of Ba/F3 cells transduced with FLT3-ITD-TKD double mutants demonstrated resistance to conventional chemotherapy in addition to tyrosine kinase inhibitors, which was associated with the activation of STAT5 and its downstream targets involved in DNA repair and antiapoptosis. 71 Age o60 years, cytogenetically normal AML, excluded FLT3-ITD þ in survival analyses.
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As predicted by this model, we hypothesize that a number of strategies may be evaluated clinically, for which candidates have emerged from laboratory research: (1) increasing the potency of FLT3 inhibition; (2) development of new multikinase inhibitors targeting simultaneously FLT3 and alternative pathways; and (3) combination therapy with inhibitors against FLT3 and alternative pathways.
MORE POTENT FLT3 INHIBITORS
The emergence of TKD mutant clones in FLT3-ITD þ AML patients treated with FLT3 inhibitors suggests that more potent FLT3 inhibitors that can target both ITD and TKD mutations may be more efficacious. Although clinical data are lacking, laboratory studies have shown promising results ( Table 5 ). The multikinase inhibitor ponatinib, which also inhibits BCR-ABL1 in CML and can overcome the hitherto highly resistant T315I mutation, 72 has been shown to induce apoptosis, and inhibit cellular proliferation and FLT3 signalling in murine myeloid cells transduced with FLT3-ITD and FLT-TKD N676D, F691I, G697R mutants. 73 In this respect, highthroughput screening for tyrosine kinase inhibitors against both FLT3-ITD and TKD may provide more candidates for laboratory and clinical trials. A caveat of this approach is that, in some cases, the resistant ITD/TKD double mutant clones have actually Figure 1 . Proposed model of clonal evolution that accounts for resistance to FLT3 inhibitor. Leukaemic clones with FLT3-ITD may acquire TKD mutation during genotoxic chemotherapy. Clones carrying both FLT3-ITD and TKD (double mutant), less sensitive to FLT3 inhibitors, are selected during treatment and lead to leukaemia progression. nCRi, near CRi. Abbreviations: AML, acute myeloid leukaemia; FLT3, fms-like tyrosine kinase 3; IC 50 , half maximal inhibitory concentration; ITD, internal tandem duplication; TKD, tyrosine kinase domain. Abbreviations: AML, acute myeloid leukaemia; CDK, cell death kinase; ERK, extracellular signal-regulated kinase; IKK2, I-kB kinase-2; MEK, mitogen-activated protein kinase/ERK kinase; mTOR, mammalian target of rapamycin; NF-kB, nuclear factor-kB; PI3K, phosphoinositide kinase-3.
a Including FLT3-TKD D835Y mutation.
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demonstrated persistently suppressed FLT3 signalling, clearly indicating that these cells escape FLT3 inhibition by surviving on alternative mechanisms during leukaemia progression. 61 
NOVEL MULTIKINASE INHIBITORS AGAINST FLT3 AND ALTERNATIVE PATHWAYS
Because the resistant ITD/TKD double mutant clones may be able to survive on FLT3-independent pathways, a number of studies have reported the development of novel multikinase inhibitors capable of inhibiting FLT3 and alternative pathways (Table 6 ). In particular, aurora kinases are highly conserved serine-threonine protein kinases that play important roles in mitosis. Selective in vitro inhibition of aurora kinases has been shown to disrupt cell cycle and cytokinesis, leading to cell death. Aurora kinase inhibitors have emerged as potential therapeutic agents in AML in clinical trials, but the overall response rate was only around 20%. 74 Recently, a novel kinase inhibitor CCT137690 targeting both FLT3 and aurora kinase has been shown to suppress the growth of MOLM-13 cells bearing double FLT3-ITD/TKD D835 mutations resistant to AC220 and sorafenib. 65 In addition, the nuclear factor-kB pathway has been shown to be activated in LIC, 75 and pharmacological inhibition of I-kB kinase-2, the enzyme that phosphorylates and hence inactivates the inhibitory subunit of nuclear factor-kB, has been shown to enhance the cytotoxicity of chemotherapy in AML blasts. 76, 77 FLT3 activation has also been shown to stimulate the nuclear factor-kB pathway. 78 On the basis of these premises, a dual FLT3-I-kB kinase-2 inhibitor AS602868 has recently been shown to inhibit cellular proliferation and induce apoptosis in Ba/F3 cells bearing FLT3-ITD and TKD, as well as in the FLT3-ITD þ human MV4-11 cell line. 78 Despite the apparent efficacies of these novel agents in the laboratory, it remains to be determined whether inhibition of aurora kinases and nuclear factor-kB may be useful clinically in suppressing the emergence of ITD/TKD double mutant clones.
COMBINATION THERAPY WITH INHIBITORS OF FLT3 AND ALTERNATIVE PATHWAYS
Novel therapeutic strategies based on combination therapy to target multiple pathogenetic signalling pathways have been reported with a view to overcoming resistance of the FLT3-ITD/ TKD double mutant clones (Figure 2 ). For instance, resistance to FLT3 inhibition has been associated with upregulation of STAT5-mediated PIM (proviral integretion site for Moloney murine leukemia virus 1) expression, which is an antiapoptotic effector. Recent reports have demonstrated that PIM inhibition suppresses the growth of FLT3-ITD þ cell lines and may function synergistically with FLT3 inhibitors in vitro. 79 On the basis of the inhibitory activity of arsenic trioxide on ERK activity, a downstream effector of FLT3 activation, combination of arsenic trioxide and the FLT3 inhibitor AG1296 has been evaluated. 80 The combination synergistically suppresses the growth and induces apoptosis in FLT3-ITD þ cell lines. Interestingly, the synergism is specific to FLT3-ITD and is not identified in leukaemia cell lines bearing wild-type FLT3. Although these therapeutic concepts have yet to be tested in clinical trials, they provide proof-of-principle observations that combinatorial targeting of multiple pathways may be exploited for treatment of drug-resistant double mutants. More candidate targets should be identified either by rational design of regimen or high-throughput chemical screening.
CONCLUSIONS
The spectacular success of multikinase inhibitors in CML represents a paradigm for the treatment of other neoplastic diseases. The constitutive activation of FLT3 by ITD and the effective targeting by FLT3 inhibitors also represents a logical therapeutic option. However, the clinical application has been limited by the invariably transient response followed by leukaemia progression. Compelling clinical and laboratory evidence has demonstrated that the resistance is due to the emergence of resistant clones carrying both FLT3-ITD and TKD mutations. Importantly, the response to FLT3 inhibition and the specific mutations arising during leukaemia progression are likely to be heterogeneous, depending on the specific AML subtypes, the sequence of the prevailing ITD as well as the specific FLT3 inhibitors used for treatment. Despite the heterogeneity, a number of recurrent issues have emerged that need to be addressed to improve the treatment outcome of patients with FLT3-ITD þ AML. These include a detailed dissection of the relative importance of ITD and TKD mutations (or mutations in other parts of FLT3) in the leukaemogenic process: the alternative survival pathways adopted by the double mutant clones, the development of potent FLT3 inhibitors against the double-resistant clones and the establishment of a robust platform whereby specific agent(s) capable of suppressing the mutant clones can be identified. The latter can be accomplished by either rational design of therapeutic strategies or high-throughput chemical screening. The clinical benefits conferred by these efforts will have to be further evaluated.
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